Angle PLC
LSE:AGL

Watchlist Manager
Angle PLC Logo
Angle PLC
LSE:AGL
Watchlist
Price: 10.5 GBX -4.55% Market Closed
Market Cap: 33.9m GBX
Have any thoughts about
Angle PLC?
Write Note

Angle PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Angle PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Angle PLC
LSE:AGL
Cash & Cash Equivalents
ÂŁ17.9m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Cash & Cash Equivalents
$568m
CAGR 3-Years
-26%
CAGR 5-Years
33%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash & Cash Equivalents
$346.4m
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
11%
EKF Diagnostics Holdings PLC
LSE:EKF
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-22%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
Creo Medical Group PLC
LSE:CREO
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-32%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cash & Cash Equivalents
$2m
CAGR 3-Years
58%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Angle PLC
Glance View

Market Cap
33.9m GBX
Industry
Health Care

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

AGL Intrinsic Value
22.18 GBX
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Angle PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
17.9m GBP

Based on the financial report for Jun 30, 2024, Angle PLC's Cash & Cash Equivalents amounts to 17.9m GBP.

What is Angle PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
24%

Over the last year, the Cash & Cash Equivalents growth was -19%. The average annual Cash & Cash Equivalents growth rates for Angle PLC have been 24% over the past three years .

Back to Top